Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05379985 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 16 to 21v12
  2. Phase: Phase 1 to Phase 1/2 Primary completion date: May 29, 2026 to May 31, 2027 · Enrollment target: 614 to 754 · Completion date: Jun 30, 2026 to Jul 26, 2027 · 2 morev11 Show 5 more changesShow less
    • Primary completion date: May 29, 2026 to May 31, 2027
    • Enrollment target: 614 to 754
    • Completion date: Jun 30, 2026 to Jul 26, 2027
    • Study description revised
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Jun 2024 to May 29, 2026 Enrollment target: 474 to 614 · Study sites: 15 to 16 · Completion date: Dec 2025 to Jun 30, 2026 · 1 morev10 Show 4 more changesShow less
    • Enrollment target: 474 to 614
    • Study sites: 15 to 16
    • Completion date: Dec 2025 to Jun 30, 2026
    • Eligibility criteria expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 14 to 15v9
  5. Study sites: 13 to 14v8
Show 6 earlier versionsHide 6 earlier versions
  1. Enrollment target: 141 to 474 Study sites: 10 to 13 · Eligibility criteria shortened, about 9 words · Study title revised · 1 morev7 Show 4 more changesShow less
    • Study sites: 10 to 13
    • Eligibility criteria shortened, about 9 words
    • Study title revised
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Study description revisedv6 See this version in full on ClinicalTrials.gov ↗
  3. Study sites: 5 to 10v5
  4. Re-verified, no change to tracked fieldsv4
  5. Study sites: 3 to 5v3
  6. Trial status: Not Yet Recruiting to Recruiting Primary endpoints revised (2) · Study sites: 0 to 3 · Start date changed from estimate of Jun 2022 to May 31, 2022 · 1 morev2 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Study sites: 0 to 3
    • Start date changed from estimate of Jun 2022 to May 31, 2022
    • Study arms: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Revolution Medicines, Inc.
16 trials monitored
See 1 trial at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
and 1 more disease
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Trial Details
NCT Number NCT05379985
Lead Sponsor Revolution Medicines, Inc.
Conditions Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Enrollment 754 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov